Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FMmeds vs WeightRx

FMmeds
Graded #257

Lower grade

vs+8.899999999999991
WeightRx
Graded #85

Higher grade

The verdict

WeightRx takes it — 72.1/100 to 63.2/100.

WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWeightRx +45
46
91
Dose & formulationFMmeds +8
72
64
Clinical oversightWeightRx +12
70
82
Labs & monitoringEven
53
53
FulfillmentFMmeds +32
97
65
Contract termsWeightRx +8
47
55
FMmeds · left barWeightRx · right bar

The numbers

MetricFMmedsWeightRx
WeighScore63.2/10072.1/100
GradeCC
Scorecard rank#257#85
Semaglutide$225/mo (all doses, compounded)$250/mo (compounded)
Tirzepatide$265/mo (all doses, compounded)$83/mo (term not published, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FMmeds

Graded #257 · C

Strengths

  • All 50 states plus DC covered, stated in the Terms
  • Operating LLC and full Manhattan Beach, CA address disclosed
  • Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
  • Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
  • Flat pricing across all dose strengths — no dose-escalation surcharge

Where it loses points

  • Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
  • Clinical network not separately named
  • LegitScript Certified, but the specific ID isn't shown
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
WeightRx

Graded #85 · C

Strengths

  • The tirzepatide figure is published up front, and it is genuinely low against the field
  • Both molecules are offered
  • No membership charge is advertised alongside the medication rate

Where it loses points

  • The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
  • Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
  • Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
  • No dose strength is published anywhere, so what the $83 buys is not stated
  • The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard